Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

970 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cytokines in cancer immunity and immunotherapy.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Smyth MJ, et al. Among authors: hayakawa y. Immunol Rev. 2004 Dec;202:275-93. doi: 10.1111/j.0105-2896.2004.00199.x. Immunol Rev. 2004. PMID: 15546400 Review.
IL-17A-producing CD30(+) Vδ1 T cells drive inflammation-induced cancer progression.
Kimura Y, Nagai N, Tsunekawa N, Sato-Matsushita M, Yoshimoto T, Cua DJ, Iwakura Y, Yagita H, Okada F, Tahara H, Saiki I, Irimura T, Hayakawa Y. Kimura Y, et al. Among authors: hayakawa y. Cancer Sci. 2016 Sep;107(9):1206-14. doi: 10.1111/cas.13005. Epub 2016 Sep 1. Cancer Sci. 2016. PMID: 27384869 Free PMC article.
Innate tumor immune surveillance.
Smyth MJ, Swann J, Hayakawa Y. Smyth MJ, et al. Among authors: hayakawa y. Adv Exp Med Biol. 2007;590:103-11. doi: 10.1007/978-0-387-34814-8_7. Adv Exp Med Biol. 2007. PMID: 17191380 Review. No abstract available.
Innate immune recognition and suppression of tumors.
Hayakawa Y, Smyth MJ. Hayakawa Y, et al. Adv Cancer Res. 2006;95:293-322. doi: 10.1016/S0065-230X(06)95008-8. Adv Cancer Res. 2006. PMID: 16860661 Review.
NKG2D and cytotoxic effector function in tumor immune surveillance.
Hayakawa Y, Smyth MJ. Hayakawa Y, et al. Semin Immunol. 2006 Jun;18(3):176-85. doi: 10.1016/j.smim.2006.03.005. Epub 2006 May 3. Semin Immunol. 2006. PMID: 16675266 Review.
IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy.
Smyth MJ, Hayakawa Y, Cretney E, Zerafa N, Sivakumar P, Yagita H, Takeda K. Smyth MJ, et al. Among authors: hayakawa y. J Immunol. 2006 May 15;176(10):6347-55. doi: 10.4049/jimmunol.176.10.6347. J Immunol. 2006. PMID: 16670347
NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y. Smyth MJ, et al. Among authors: hayakawa y. J Exp Med. 2004 Nov 15;200(10):1325-35. doi: 10.1084/jem.20041522. J Exp Med. 2004. PMID: 15545356 Free PMC article.
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, Smyth MJ, Darcy PK. Kershaw MH, et al. Among authors: hayakawa y. J Immunol. 2004 Aug 1;173(3):2143-50. doi: 10.4049/jimmunol.173.3.2143. J Immunol. 2004. PMID: 15265951
Regulation of antitumour immunity by CD1d-restricted NKT cells.
Swann J, Crowe NY, Hayakawa Y, Godfrey DI, Smyth MJ. Swann J, et al. Among authors: hayakawa y. Immunol Cell Biol. 2004 Jun;82(3):323-31. doi: 10.1111/j.0818-9641.2004.01254.x. Immunol Cell Biol. 2004. PMID: 15186264 Review.
Interleukin 21: a key player in lymphocyte maturation.
Nutt SL, Brady J, Hayakawa Y, Smyth MJ. Nutt SL, et al. Among authors: hayakawa y. Crit Rev Immunol. 2004;24(4):239-50. doi: 10.1615/critrevimmunol.v24.i4.20. Crit Rev Immunol. 2004. PMID: 15588224 Review.
970 results
Jump to page
Feedback